Abstract:BACKGROUND New oncology drug development has moved from general cytotoxic agents to molecular target-directed therapeutics. Consequently, there is a need to identify tumor types and individual patient tumors that express the target and could benefit from more selective therapies in clinical trials. Therefore, the in vivo models used in preclinical development should be\#8220;disease-oriented\#8221;and target-directed. Recently, we developed non-small cell lung cancer (NSCLC) xenograft models by transplanting human fresh tumor fragments into nude mice (HuPrimeTM), which have been used for test of cytotoxic and targeted anticancer agents. METHODS The fresh NSCLC tumor samples were collected from local hospitals. The tumor fragments of 1-2 mm were subcutaneously implanted in the flanks of the Balb/c nude mice. In the first passage, tumors derived from male patients were implanted into male mice, and tumors from women were inoculated into female mice. All therapeutic efficacy experiments used female mice. The test drugs included paclitaxel, gemcitabine, and the epidermal growth factor receptor (EGFR) inhibitor erlotinib. The EGFR and K-ras mutation status were investigated and compared with their efficacy results. RESULTS A total of 72 NSCLC samples were implanted into nude mice, and 13 HuPrimeTM tumor models were established with a tumor taking rates of 18% for the first passage. The tumor taking rates were higher in the second and third passages ranged from approximately 80-100%. The HuPrime tumor xenografts\#8217; architecture, the cell and histopathological morphology from the three generations mirrored in most of cases the original patient cancers. The mutations for EGFR and K-ras among the tested tumor samples were 56% and 22%, respectively. The two cytotoxic drugs paclitaxel and gemcitatbine produced tumor growth inhibition rates ranged from 50-53% regardless of the EGFR and K-ras mutation status. While erlotinib demonstrated a significant antitumor activity only in the tumors with EGFR mutation and wild-type K-ras, which were consistent with their clinical findings. CONCLUSIONS These results suggest that HuprimeTM tumor xenograft models provide a unique renewable source of tumor material for test of novel anticancer agents. They may predict more relevant clinical response rates and higher correlation with clinical findings than use of traditional xenograft models established from long-term cultured cancer cell lines. Especially, they have advantages for test of target-oriented therapeutics in new drugs development programs. Citation Information: In: Proc Am Assoc Cancer Res; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr LB-65.

Antitumor Activity of Axitinib in Lung Carcinoids: A Preclinical Study

Exploring the multifaceted antitumor activity of axitinib in lung carcinoids

Phase II Clinical Trial of Axitinib and Avelumab in Patients With Recurrent/Metastatic Adenoid Cystic Carcinoma

The multikinase inhibitor axitinib in the treatment of advanced hepatocellular carcinoma: the current clinical applications and the molecular mechanisms

Abstract LB342: Potent Anti-Tumor Activity Demonstrated by Anti-AXL CAR T Cell Therapy and AXL-ADC in Lung Cancer and Breast Cancer Models

CLM94, a novel cyclic amide with anti-VEGFR-2 and antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo

Anlotinib Suppresses Lymphangiogenesis and Lymphatic Metastasis in Lung Adenocarcinoma Through a Process Potentially Involving VEGFR-3 Signaling.

Axitinib, a selective inhibitor of vascular endothelial growth factor receptor, exerts an anticancer effect in melanoma through promoting antitumor immunity.

Abstract #LB-65: Test of Cytotoxic and Targeted Anticancer Drugs Using Human Primary Non-Small Cell Lung Cancer Xenograft Models

The Diagnostic Value of ACSL1, ACSL4, and ACSL5 and the Clinical Potential of an ACSL Inhibitor in Non-Small-Cell Lung Cancer

Alectinib in Early-Stage Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: Current Evidence and Future Challenges

Axitinib Targeted Cancer Stem Like Cells to Enhance Efficacy of Chemotherapeutic Drugs Via Inhibiting the Drug Transport Function of Abcg2

Axitinib: from preclinical development to future clinical perspectives in renal cell carcinoma

Angiogenesis Inhibitors in Small Cell Lung Cancer

Inhibitors of the anaplastic lymphoma kinase

Abstract A11: Antitumor activity of targeted and cytotoxic agents in xenograft models correlates with clinical response: A pharmacokinetic-pharmacodynamic analysis.

Synergistic Antitumor Effects of Anlotinib Combined with Oral 5-Fluorouracil/S-1 via Inhibiting Src/AKT Signaling Pathway in Small-Cell Lung Cancer

Combined Treatment of Apatinib with Docetaxel in Non-Small-Cell Lung Cancer Mice and Its Material Basis of Pharmacokinetics.

Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial

Role of anlotinib-induced CCL2 decrease in anti-angiogenesis and response prediction for non-small cell lung cancer therapy.

Therapeutic Senolysis of Axitinib-Induced Senescent Human Lung Cancer Cells